ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action

New York, NY–(Newsfile Corp. – January 4, 2025) – WHY? The Rosen Law Firm, a global investor protection law firm, reminds purchasers of Humacyte, Inc. (NASDAQ: HUMA ) securities between May 10, 2024 and October 17, 2024, both dates inclusive (“Class period”) important part. January 17, 2025 lead plaintiff deadline.

SO WHAT?If you purchased Humacyte securities during the Class Period, you may be entitled to a refund without payment of any cash fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT? To join the Humacyte class action, visit https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. 866-767-3653 or email email case@rosenlegal.com for more information.A class action lawsuit has already been filed. If you want to act as the main plaintiff, you must move to court no later than January 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in leading the litigation.

WHY CHOOSE ROSEN LAW?We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices do not have comparable experience, resources or the recognition of any meaningful peers. Many of these firms do not actually handle securities class actions, but are simply brokers who refer clients or are partners with the law firms that actually litigate the cases. Be Wise When Choosing Counsel The Rosen Law Firm represents investors worldwide, focusing its practice in securities class action and shareholder derivative litigation #1 rating by ISS Securities Class Action: (WA:) Services for securities class actions in 2017. The company has been ranked in the top 4 every year since 2013 and has returned hundreds of millions of dollars to investors in 2019 alone. In 2020, founding partner Lawrence Rosen was named a titan of plaintiffs’ attorney by law360.Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASEAccording to the lawsuit, during the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: ; (2) the Food and Drug Administration’s (“FDA”) review of the Biologics License Application (“BLA”) will be delayed until Humacyte has remedied these deficiencies; and (3) as a result, there was a significant risk to the FDA’s approval of a cell-tissue vessel (“ATEV”) for vascular trauma; and (4) as a result of the above, the defendants’ positive statements about Humacyte’s business, operations and prospects were materially misleading and/or lacked a reasonable basis.When the true details came to market, the suit alleges, investors suffered damages.

To join the Humacyte class action, visit https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com.

No class has been certified. You may not be represented by an attorney. You may also choose to remain an absent class member at this time potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn at https://www.linkedin.com/company/the-rosen-law-firm , on Twitter at https://twitter.com/rosen_firm or on Facebook ( NASDAQ: ). https:/ /www.facebook.com/rosenlawfirm/.

Advertisement of a lawyer. Previous results do not guarantee a similar result.

——————————

Contact information.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/236071